SELLAS Life Sciences Group, Inc. - Common Stock (SLS)

The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups.

Shkreli argued that the company lacks a clear mechanism of action and strong clinical data.

Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon.

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

The stock's recent surge has been driven by anticipation around the late-stage Regal trial evaluating its leukemia therapy Galinpepimut-S (GPS).

Short interest has risen about 15% since the December update on the Phase 3 Regal trial.

The rally comes ahead of results from the Phase 3 Regal trial testing Galinpepimut-S (GPS) as a maintenance treatment for AML patients.

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.

According to Stocktwits data, message volume on the platform surrounding the stock increased nearly 170% over the past 24 hours.

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS.

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover.

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.

The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia.

Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams.